Background: Autosomal dominant familial cortical myoclonic tremor and epilepsy (FCMTE) is characterized by distal tremulous myoclonus, generalized seizures,
Introduction
Autosomal dominant familial cortical myoclonic tremor and epilepsy (FCMTE) has over the years accumulated several names and acronyms including autosomal dominant cortical myoclonus and epilepsy (ADCME), benign adult familial myoclonic epilepsy (BAFME), cortical tremor (Crt Tr), familial adult myoclonic epilepsy (FAME), familial cortical myoclonic tremor (FCMT), familial cortical tremor with epilepsy (FCTE), familial essential myoclonus and epilepsy (FEME), familial benign myoclonus epilepsy of adult onset (FMEA), and heredofamilial tremor and epilepsy movements are usually the first symptom, usually with an onset in the second or third decade. Seizures, most often unprovoked generalized tonic-clonic seizures without aura, start later in life, frequently in the third or fourth decade. Diagnosis is based on clinical characteristics and family history, and is supported by electrophysiological investigations, after exclusion of other tremulous disorders and epileptic syndromes. Treatment is symptomatic, usually with anti-epileptic drugs such as valproate and clonazepam.
Additional symptoms have also been described, possibly extending the spectrum of the disease. These include mild cognitive decline [8] [9] [10] [11] [12] but also psychiatric symptoms, 13 nystagmus, 14 and migraine. [15] [16] [17] [18] Clinical anticipation has been described in Asian pedigrees. [19] [20] [21] It is unknown which of these symptoms are part of FCMTE or are co-incidental, and which symptoms might differentiate between underlying genetic mutations. FCMTE maps to different loci including 8q23.3-q24. 13 has been identified in an Egyptian family where a mutation has been localized in the contactin 2 (CNTN2) gene, which is associated with potassium channel stability. 45 In autosomal dominant FCMTE, several possible gene mutations have been proposed as causative on the FCMTE loci. 27, [46] [47] [48] [49] Recently, a mutation was found in a Dutch FCMTE3 pedigree in the catenin delta 2 (CTNND2) gene, supported by functional tests. 39 Neurophysiological, imaging, genetic, and pathology findings have shed some light on the pathophysiology underlying FCMTE. A cortical origin of the myoclonus in FCMTE is proven by electrophysiological investigation consistent with reduced cortical inhibition.
14 Pathology findings in a Dutch FCMTE pedigree indicate Purkinje cell changes, resembling the abnormal neuronal morphology in Ctnnd2 mutant mice. 1, 39, 50 Congruent imaging findings include decreased fiber density, 51 functional connectivity alterations 52 and gray matter loss in the cerebellar motor area. 53 It has been hypothesized that, via the cerebello-thalamo-cortical loop, reduced input from the cerebellum can lead to cortical hyperexcitability. 54 However, the question arises if the cerebellum is the primary generator of cortical hyperexcitability in all FCMTE types. Alternatively, cortical functional changes could underlie the symptoms, with or without coexisting cerebellar pathology. This review will bring together evidence concerning the clinical spectrum including treatment on the one hand, and, on the other hand, pathophysiological and genetic studies, adding the latest insights. 1 The current review aims to not only summarize studies into FCMTE, but also be of guidance to the clinician encountering a patient with suspected FCMTE. A second aim is to link insights from pathophysiological studies to genetic studies to better understand the underlying disease mechanisms and be a guide for future research and better treatment of these patients.
Methods
We conducted a PubMed search on November 15, 2017, for the period January 1, 2011, to November 15, 2017, using a combination of the following search terms: cortical tremor, myoclonus, epilepsy, benign course, adult onset, familial, autosomal dominant, and the different acronyms for FCMTE fully written; see Appendix A for complete search terms. The search delivered a total of 1,180 articles, and one additional from reference lists, from which 33 fulfilled the selection criteria (flow chart, Figure 1 ). The search conducted for our previous review in 2011 had already revealed a total of 44 publications published before 2011, 1 which are also included in the current review (Tables 2 and 3) . Included were reports published in English describing pedigrees with the following diagnostic criteria as previously reported: 1 1) distal action and postural tremor/fine myoclonus; 2) generalized tonic-clonic seizures and/or electrophysiological features of cortical reflex myoclonus including giant somatosensory evoked potentials (SEPs) and/or enhanced long loop reflexes (LLRs/C reflex); and 3) a family history of tremor/epilepsy consistent with autosomal dominant inheritance. Excluded were pedigrees and cases with another cause for tremor and epilepsy (including autosomal recessive FCMTE 45 ), structural lesions on magnetic resonance imaging (MRI), and additional symptoms such as clear parkinsonism, dementia, and/or ataxia pointing to a different syndrome. 1 For an overview of additional pedigrees since our last review 1 see Table 2 . Table 3 shows the pedigrees previously identified. 1 Since 2011, 70 additional pedigrees in 33 publications, including 48 from India, have been extensively described (providing clinical and electrophysiological data, Table 2) . [16] [17] [18] 21, 27, 40, 41, 43, [46] [47] [48] [55] [56] [57] [58] [59] Descriptions of the pedigrees comply with autosomal dominant inheritance. The reports used uniform criteria for diagnosing FCMTE, and one paper explicitly stated they used the diagnostic criteria from our last review. 55 The reports vary in detail in their description of the neurological examination, the presence or absence of cerebellar signs, of cognitive assessment, comorbid psychiatric disorders, effect of anti-epileptic drugs on tremor/epileptic seizures, drug dosage, clinical anticipation, structural imaging, and electrophysiological investigation including jerk-locked back averaging (JLA). Owing to insufficient clinical/electrophysiological data, several new families were not included in Table 2 . 13, 19, 20, 29, 60 Figure 1. Article Selection Flowchart. Literature search for the identification of new pedigrees, genetic/linkage or imaging studies since our last review. The results section covers both the previously identified and novel pedigrees. The tremulous movements are in fact small, high-frequency myoclonic jerks, induced by posture or action. They can be mild, but can also be more incapacitating. 17 .
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GTC, F, A, M n.d. (Tables 2  and 3 ). EMG shows arrhythmic/semi-rhythmic high-frequency (>10 per second) burst-like discharges of about 50 ms, which can be synchronous between agonist and antagonist muscles, typical for cortical myoclonus. 71 Often features of cortical reflex myoclonus are present, including giant SEP, enhanced LLR, and/or cortical spikes preceding myoclonus with JLA. 71 Imaging. Structural imaging with MRI is normal in most cases. Although slight cerebellar atrophy (e.g., vermis) 10 has been described. [9] [10] [11] 48 In one patient corticospinal degeneration was present. 48 In three patients basal ganglia/periventricular white matter changes were observed.
10
Treatment. One report observed a reduction in tremulous movements from a b-blocker. 16 One to three AEDs usually prevents seizures or reduces them to once a year. Gabapentin has been reported to precipitate myoclonic status.
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Pathophysiology
Cortical hyperexcitability can be considered the hallmark of FCMTE. However, cerebellar changes have been described in neuroimaging and pathology studies.
Cortical hyperexcitability. Electrophysiological findings in FCMTE point to cortical hyperactivity and a cortical origin of the tremulous myoclonic movements. Functional (f)MRI-EMG also indicated cortical activity linked to the tremulous movements. 77 Transcranial magnetic stimulation (TMS) in European pedigrees revealed a reduction in short interval cortical inhibition compared with healthy controls, reflecting hyperexcitability of the cortex. 9, 14 In Japanese FCMTE patients the giant SEP was enhanced, lacking the long-term depression effect seen in healthy controls after quadripulse TMS over the primary motor cortex. 78 However, post-mortem pathology studies in three Dutch cases revealed limited involvement of the sensorimotor cortex. In family members of these deceased Dutch patients a mutation was found in the CTNND2 gene that led to abnormal neuronal sprouting in mice neurons, resembling the aforementioned cerebellar pathology. 39 Moreover, imaging findings in the same pedigree showed decreased cerebellar fiber density 51 and gray matter loss in the cerebellar motor area. 53 In a Chinese pedigree in which 8q and 2p linkage was excluded, MRS indicated cerebellar dysfunction 65 and a fMRI study indicated alterations between the cerebellum and supratentorial structures after network analysis. 52 A South African pathology case, from a pedigree in which 8q and 2p linkage was excluded, revealed focal Purkinje cell loss, neuronal atrophy in the dentate nucleus, and neuronal loss with gliosis in the olives and pallidum.
10
Other findings. A functional MRI/voxel-based morphometry (VBM) study indicated gray matter loss in cortical and subcortical structures with connectivity alterations. 70 In a resting state fMRI study, compared to ET and healthy controls, the right fusiform gyrus and the posterior cingulate cortex showed decreased amplitude of low-frequency fluctuation (ALFF), and the frontal lobe showed increased ALFF that correlated with disease duration. 55 In two FCMTE patients with gait difficulties but no benefit from L-dopa in one, MRI showed frontal atrophy and single positron emission computed tomography (SPECT) showed dopamine depletion. 61 In a FCMTE patient with a language disorder and short-term memory problems, MRI showed frontal In the Dutch family after WES, a mutation was found in the CTNND2 gene. 39 Knockdown of Ctnnd2 in cortical mouse neurons led to abnormal neuronal sprouting which resembled abnormal Purkinje cell morphology in deceased FCMTE patients. 39 However, in the French family a mutation in SEMA5A (semaphorin-5A) and CTNND2 genes was excluded using direct sequencing. 36 Carr et al. 10 have named their South African pedigree FAME3; however, only analysis to exclude the linkage areas 2p and 8q was performed. FCMTE4, with linkage to 3q26.32-3q28, has recently been discovered in a Thai family. 43 No causative gene has yet been identified.
Two candidate genes have been proposed for FCMTE4: HTR3D (5-hydroxytryptamine receptor 3D) and KCNMB3 (calcium-activated Other proposed mutations include a missense mutation on 8q22.3 in ubiquitin protein ligase E3 component n-recognin 5 (UBR5) within a Japanese pedigree, linked to Angelman syndrome and autosomal recessive juvenile parkinsonism. 59 In a Chinese family, a missense mutation at 22q13.1 in PLA2G6 (phospholipase A2 Group VI) was found using WES. 47 Pathogenicity is hypothetical. PLA2G6 mutations have also been linked to infantile neuroaxonal dystrophy and the enzyme encoded by PLA2G6 is involved in the synthesis of arachidonic acid; abnormal metabolism of arachidonic acid could lead to neuronal hyperexcitability. 47 Genetic findings in FCMTE-like disorders. In a family from Canada with familial cortical myoclonus without seizures (a potential new disorder), linkage analysis and WES identified a missense mutation on 16q22.1 in the nucleolar protein 3 (NOL3) gene. 49 Pathogenicity is doubtful because Nol3 knockout mice did not exhibit myoclonic symptoms and had normal SEPs. 49 Moreover there is an autosomal recessive form of FCMTE, caused by a single base pair deletion in CNTN2, crucial for the stability of potassium channels.
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Discussion
In this systematic review we included a total of 126 FCMTE pedigrees (761 patients), including 70 additional FCMTE pedigrees (275 patients) since our 2012 review. 1 Here we discuss the diagnostic criteria, clinical spectrum, and treatment. Also, we suggest features that might relate a phenotype to a specific genotype, and focus on the pathophysiology combining neurophysiological, imaging, and pathology studies, as well as on potential candidate genes.
Diagnostic criteria and clinical spectrum
The pedigrees presented in this review share the core features of FCMTE, including autosomal dominant inheritance, distal myoclonic tremor with signs of cortical reflex myoclonus, and/or generalized tonic-clonic seizures. Myoclonus is typically the first symptom, while seizures, usually occurring later in the disease course, are a common reason for patients to seek medical care. However, seizures might in a number of cases be the first symptom.
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EEG findings in FCMTE include generalized spikes/waves and photoparoyxsmal or photomyogenic responses. Other possible clinical features include mild progression of symptoms with aging, 16, 17, 21, [57] [58] [59] and proximal myoclonus, potentially leading to gait disorders, across linkage types or European/Asian descent. 16, 17, 37, 46, [56] [57] [58] 61, 65, 67 Both are not major inclusion criteria but phenomena that are frequently observed and seem to be part of the disease spectrum. Focal EEG abnormalities and a slower posterior dominant rhythm might be features of FCMTE. 56, 74 Also, EEG may show generalized spikes and waves preceding later onset of epilepsy.
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FCMTE is differentiated from other tremor-like disorders (including ET) with electrophysiological recordings. 32 FCMTE can be differentiated from the progressive myoclonus epilepsy syndromes and juvenile myoclonic epilepsy (JME) in the absence of severe cognitive decline and absence of severe ataxia. 82 Unlike FCMTE, JME presents with myoclonus in the morning and shows no features of cortical reflex myoclonus. 82 Criteria for the diagnosis of FCMTE are the following:
1) Distal action and postural tremor/fine myoclonus, accompanied by generalized tonic-clonic seizures in at least one family member. Also, mild progression of symptoms with aging and proximal muscle myoclonus can be present.
2)
Electrophysiological measures support the diagnosis: giant SEP and LLR point to cortical hyperexcitability; polymyography showing discharges of ,50 ms suggest cortical myoclonus; and EEG-EMG coherence analysis or JLA can support a cortical origin of the tremulous movements.
3)
Autosomal dominant inheritance of epilepsy and ''tremor''/ myoclonus within the family.
4)
No other cause for tremor, epilepsy. No other symptoms must be present like ataxia, parkinsonism, dementia, dystonia, spasticity.
Are phenotypical differences related to specific mutations?
Differences in symptomatology have been reported, possibly linked to different mutations.
1 Japanese and Chinese pedigrees, linked to 8q (FCMTE1; also known as BAFME) suffer from a more ''benign'' form of FCMTE with age of onset in the third decade, infrequent seizures, and no cognitive decline. 24, 25, 27 Usually, FCMTE1 patients present with rhythmic distal myoclonus of the upper extremities, but more extensive involvement of the lower extremities and facial muscles has also been reported. 24, 68, 83 Pedigrees with linkage to 2p (FCMTE2) exhibit a more severe form of myoclonus (proximal involvement) that progresses with aging and leads to gait disability. 16, 17, 46 Specific for Italian 2p pedigrees, psychiatric comorbidity is frequently present. 13 Atypical symptoms in pedigrees with a possibly pathogenic mutation were present in Spanish 2p ACMSD patients (n:1 parkinsonism and mild ataxia) 48 and in 2p ADRA2B patients (focal seizures and age-related dementia). 46 Linkage to 5p (FCMTE3) in two Chinese pedigrees is related to a benign course with age of onset in the fourth decade, and, during short-term follow-up, no disease progression. 40, 41 However, in French FCMTE3 pedigrees, progression of symptoms, gait disability, frontal syndrome, cognitive changes, and logopenic syndrome were described. 61, 67 Also, in a Dutch FCMTE3 pedigree subjective cognitive decline was present.
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In a Thai pedigree, with linkage to 3q (FCMTE4), myoclonus presented earlier, in the second decade, and seizures started in the third decade. 43 No cognitive decline was present.
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In patients with unknown linkage the following findings were reported: clinical anticipation was present in Asian pedigrees (measured with rating scales). [19] [20] [21] Mild cognitive decline was present in Asian patients. 21 Further evidence for cerebellar involvement in FCMTE arises from imaging studies in FCMTE, indicating functional connectivity changes between the cerebellum and cortical/subcortical structures. 52 Supratentorial gray matter loss outside the motor circuit might be secondary. 70 Also, cerebellar atrophy and ataxia have frequently been noted in patients with epilepsy. 87 Repetitive TMS over the cerebellar cortex was able to reduce seizure frequency in drug-resistant epilepsy. 87, 88 The cerebellum might be involved in psychiatric disorders. 89 In several FCMTE pedigrees anxiety and depressive comorbidity was reported. 13, 56 With aging, Purkinje cells become atrophic in healthy adults and the amount of white matter is reduced in the cerebellum. 90 The degeneration of Purkinje cells might be enhanced in FCMTE patients leading to defective compensatory input to cortical structures. Clinically, this could explain the later onset of seizures and the worsening of symptoms with aging. 16 Moreover, cortical hyperexcitability seems to increase with aging in Japanese patients, reflected by higher giant SEP amplitude. 73 Pathology, imaging, genetic, and clinical findings indicate cerebellar changes. This offers a possible explanation for the decreased cortical inhibition. Deficient stimulation of the dentate nucleus by Purkinje cells in the cerebellum may lead to increased cortical facilitation via the cerebello-thalamo-cortical loop, a hypothesis already raised for cortical myoclonus and epilepsy. 54, 87, 91 Purkinje cell changes might however not be the (sole) explanation for the symptoms observed in FCMTE. The cerebellar changes might be specific for certain FCMTE types, with the strongest evidence for FCMTE3. Future research is needed to indicate whether cerebellar involvement, including pathological cerebellar changes, is a general finding in FCMTE. In some FCMTE types it might be co-existent, secondary due to primary cortical pathology, or even absent.
Possible candidate genes
Possible candidate causative genes include a trinucleotide repeat expansion or channelopathy. 80 Purkinje cell changes in deceased Dutch FCMTE patients show striking similarities with those found in spinocerebellar ataxia (SCA) type 6, characterized by ataxia and downbeat nystagmus. 1, 50 Patients from the same Dutch FCMTE pedigree also have a downbeat nystagmus. 14 SCA type 6 is caused by a CAG repeat in a calcium channel CACNA1A heavily expressed in the cerebellum. 92 Other observations that might also point to a trinucleotide repeat expansion or channelopathy underlying FCMTE include in Asian FCMTE pedigrees, progressively earlier onset of the disease with increasing severity in successive generations [19] [20] [21] ; presence of migraine [15] [16] [17] [18] analogues to hemiplegic migraine with mutations in calcium channels 93 ; and the recognition that certain epilepsy syndromes are channelopathies. 45, 94 Recently, an autosomal recessive form of FCMTE has been recognized with a single base pair deletion in CNTN2, crucial for the stability of potassium channels. 45 A channelopathy could involve cerebellar cells and/or induce functional cortical changes.
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Several genes have been identified as potentially causative in FCMTE. A gain of function mutation in the ADRA2B gene has been found in Italian FCMTE2 pedigrees that could potentially alter the neuronal firing pattern and even reduce gamma-aminobutyric acid (GABA) neurotransmission. 46 A reduction in cortical GABA neurotransmission has been associated with cortical myoclonus in rats, progressive myoclonus epilepsy and Unverricht-Lundborg disease characterized by cortical myoclonus and ataxia along with seizures. 91 Treatment with AEDs increasing GABA neurotransmitter levels can relieve the symptoms of FCMTE. Another neurotransmitter implied in the pathophysiology of FCMTE2 is serotonin. 48 A mutation in the ACMSD gene, encoding for an enzyme that is part of the kynurenine pathway, might lead to the accumulation of waste products. 48 In mice, seizures could be induced when injecting these kynurenines in the brain ventricles. 95 In Dutch FCMTE3 patients, a mutation in CTNND2, supported by functional tests in mice, seems to be responsible for abnormal neuronal sprouting. 39 Hypothetically, the pathology findings in the cerebellum and the disease itself are caused by the CTNND2 mutation.
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Other proposed mutations/linkage studies have not yet elucidated the pathophysiology of FCMTE and have provided conflicting results, including proposed mutations outside the known linkage areas (UBR5, PLA2G6) 47, 59 and a pedigree from Canada (NOL3 mutation) 49 without seizures, possibly reflecting another illness. The lack of progress might be due to the inability of next-generation sequencing techniques to detect exon rearrangements, trinucleotide repeat expansion, and copy number variants. 80 Even a deletion in an intron might lead to defective splicing of a gene as in Unverricht-Lundborg disease. 96 New algorithms and WGS might lead to a breakthrough. 97, 98 Future genetic studies should focus on mutations in proteins expressed in the cerebellum, involved in neuronal outgrowth, calcium, sodium, or potassium signaling, GABA neurotransmission, and genes which interact with the SCAs or other diseases with cortical myoclonic symptoms. 80 
Limitations
Reporting bias may have influenced our results. The number of patients and follow-up differ between pedigrees. Across studies, rating scales for motor symptoms and cognitive functioning differ or have not been reported. Therefore, symptoms might have been underreported, for instance cerebellar dysfunction and cognitive deterioration in certain pedigrees.
14 Additional investigations (MRI, electrophysiology, pathology) have not always been performed, in some cases leading to diagnostic uncertainty, but more often raising questions with respect to generalizability of findings across pedigrees. For instance, both the imaging and the pathology findings involving cerebellar changes have largely been confined to a South African patient (linkage exclusion 2p, 8q), a Dutch pedigree (FCMTE3), and Chinese patients (linkage exclusion 2p, 8q) making the generalizability of the findings problematic.
10,39,51-53, 65, 70 Several mutations (ACMSD, ADRA2B, UBR5, PLA2G6) have been proposed but pathogenicity has still to be proven. [46] [47] [48] 59 Conclusion FCMTE, also known under different names and acronyms, is a clinical entity not (yet) listed by the ILAE. It is characterized by cortical tremor/fine myoclonus and generalized tonic-clonic seizures with autosomal dominant inheritance. Proximal myoclonus and mild progression with aging are part of the spectrum. Electrophysiology recordings show features of cortical reflex myoclonus. Valproate (not recommended in women of childbearing age) or levetiracetam, with or without clonazepam reduce symptoms. Gabapentin should be prescribed cautiously.
FCMTE is a heterogeneous disorder, and is likely to include a variety of different conditions with mutations of different genes. Additional symptoms have frequently been reported and can be co-incidental or based on genetic differences. Pathophysiological mechanisms remain to be elucidated, but pathology, genetic, and imaging studies have given clues that indicate cerebellar involvement. The cerebellar changes might lead to reduced cortical inhibition. Alternatively, underlying genetic changes induce both cerebellar and cortical changes. Genetic heterogeneity is present in linkage studies. Several causative genes have been suggested. However, functional tests have not always been performed.
Pathophysiology and genetic studies indicate that future genetic studies should focus on mutations involving Purkinje cell outgrowth, channelopathies, or genes responsible for neurotransmitter synthesis. 
